JP7433303B2 - ヒト免疫不全ウイルス複製の阻害剤 - Google Patents

ヒト免疫不全ウイルス複製の阻害剤 Download PDF

Info

Publication number
JP7433303B2
JP7433303B2 JP2021515492A JP2021515492A JP7433303B2 JP 7433303 B2 JP7433303 B2 JP 7433303B2 JP 2021515492 A JP2021515492 A JP 2021515492A JP 2021515492 A JP2021515492 A JP 2021515492A JP 7433303 B2 JP7433303 B2 JP 7433303B2
Authority
JP
Japan
Prior art keywords
alkyl
chloro
methyl
compound
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021515492A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022501370A (ja
JPWO2020058844A5 (https=
JP2022501370A5 (https=
Inventor
イウアグウ，クリスティアナ
エム． ピース，ケヴィン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViiV Healthcare UK No 5 Ltd
Original Assignee
ViiV Healthcare UK No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ViiV Healthcare UK No 5 Ltd filed Critical ViiV Healthcare UK No 5 Ltd
Publication of JP2022501370A publication Critical patent/JP2022501370A/ja
Publication of JPWO2020058844A5 publication Critical patent/JPWO2020058844A5/ja
Publication of JP2022501370A5 publication Critical patent/JP2022501370A5/ja
Application granted granted Critical
Publication of JP7433303B2 publication Critical patent/JP7433303B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021515492A 2018-09-20 2019-09-17 ヒト免疫不全ウイルス複製の阻害剤 Active JP7433303B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862733692P 2018-09-20 2018-09-20
US62/733,692 2018-09-20
PCT/IB2019/057814 WO2020058844A1 (en) 2018-09-20 2019-09-17 Inhibitors of human immunodeficiency virus replication

Publications (4)

Publication Number Publication Date
JP2022501370A JP2022501370A (ja) 2022-01-06
JPWO2020058844A5 JPWO2020058844A5 (https=) 2022-09-05
JP2022501370A5 JP2022501370A5 (https=) 2022-09-05
JP7433303B2 true JP7433303B2 (ja) 2024-02-19

Family

ID=68000004

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021515492A Active JP7433303B2 (ja) 2018-09-20 2019-09-17 ヒト免疫不全ウイルス複製の阻害剤

Country Status (4)

Country Link
US (1) US11919897B2 (https=)
EP (1) EP3853228A1 (https=)
JP (1) JP7433303B2 (https=)
WO (1) WO2020058844A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021004593A (es) 2018-10-24 2021-06-15 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
US20210395262A1 (en) * 2018-10-24 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP3873607B1 (en) * 2018-10-29 2023-11-29 VIIV Healthcare UK (No.5) Limited Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication
SG11202107145SA (en) 2019-01-25 2021-08-30 Univ Brown Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑
TWI902729B (zh) 2019-11-28 2025-11-01 日商鹽野義製藥股份有限公司 以組合整合酶阻礙劑及抗ｈｉｖ藥為特徵之ｈｉｖ感染症的預防及治療用醫藥
KR20220151655A (ko) * 2020-03-06 2022-11-15 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제
CN115397424A (zh) * 2020-04-15 2022-11-25 Viiv保健英国第五有限公司 人类免疫缺陷病毒复制的抑制剂
US20250042926A1 (en) * 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
AR132951A1 (es) 2023-06-15 2025-08-13 Viiv Healthcare Uk No 5 Ltd Métodos e intermedios para preparar compuestos
US12594276B2 (en) 2024-02-05 2026-04-07 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008546843A (ja) 2005-06-27 2008-12-25 アムゲン インコーポレイティッド 抗炎症性アリールニトリル化合物
JP2016504392A (ja) 2013-01-09 2016-02-12 ギリアード サイエンシーズ， インコーポレイテッド 抗レトロウイルス剤としての（ヘテロ）アリールアセトアミド誘導体
JP2017525722A (ja) 2014-08-29 2017-09-07 ギリアード サイエンシーズ， インコーポレイテッド 抗レトロウイルス剤

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
EP2729448B1 (en) 2011-07-06 2015-09-09 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
CA2897268C (en) 2013-01-09 2018-12-04 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
CA2896244C (en) 2013-01-09 2017-07-04 Gilead Sciences, Inc. 5-membered heteroaryls and their use as antiviral agents
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
KR20230011471A (ko) 2016-08-19 2023-01-20 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물
TW201906834A (zh) 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
US10836746B2 (en) 2018-02-15 2020-11-17 Gilead Sciences, Inc. Therapeutic compounds
WO2019161280A1 (en) 2018-02-16 2019-08-22 Gilead Sciences, Inc. Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008546843A (ja) 2005-06-27 2008-12-25 アムゲン インコーポレイティッド 抗炎症性アリールニトリル化合物
JP2016504392A (ja) 2013-01-09 2016-02-12 ギリアード サイエンシーズ， インコーポレイテッド 抗レトロウイルス剤としての（ヘテロ）アリールアセトアミド誘導体
JP2017525722A (ja) 2014-08-29 2017-09-07 ギリアード サイエンシーズ， インコーポレイテッド 抗レトロウイルス剤

Also Published As

Publication number Publication date
US11919897B2 (en) 2024-03-05
US20210323961A1 (en) 2021-10-21
JP2022501370A (ja) 2022-01-06
WO2020058844A1 (en) 2020-03-26
EP3853228A1 (en) 2021-07-28

Similar Documents

Publication Publication Date Title
JP7433303B2 (ja) ヒト免疫不全ウイルス複製の阻害剤
JP7361766B2 (ja) ヒト免疫不全ウイルス複製の阻害剤
JP7500555B2 (ja) ヒト免疫不全ウイルス複製の阻害剤
JP7532354B2 (ja) ヒト免疫不全ウイルス複製の阻害剤
JP7398448B2 (ja) ヒト免疫不全ウイルス複製の阻害剤
US20240374598A1 (en) Inhibitors of human immunodeficiency virus replication
JP2022509919A (ja) ヒト免疫不全ウイルス複製の阻害剤
ES2969030T3 (es) Derivados de quinazolinil-indazol y su uso como inhibidores de replicación de virus de inmunodeficiencia humana
ES2974657T3 (es) Derivados de n-substituido-6-oxo-1,6-dihidropirimidina-2-ilo como inhibidores de la replicación del virus de inmunodeficiencia humana
KR20220151655A (ko) 인간 면역결핍 바이러스 복제의 억제제
EA043730B1 (ru) Ингибиторы репликации вируса иммунодефицита человека

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220826

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240206

R150 Certificate of patent or registration of utility model

Ref document number: 7433303

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150